Metabolism and Drug Interactions of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Transplant Patients-Reference-Cited by-同舟云学术

Metabolism and Drug Interactions of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors in Transplant Patients

Published:1998-10 Issue:1 Volume:80 Page:1-34
ISSN:0163-7258
Container-title:Pharmacology & Therapeutics
language:en
Short-container-title:Pharmacology & Therapeutics

Author:

Christians Uwe,Jacobsen Wolfgang,Floren Leslie C.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Pharmacology

Reference316 articles.

1. Hyperlipidaemia in renal transplant patients;Aakhus;J. Intern. Med.,1996

2. Abouljoud, M. S., Levy, M. E., Klintmalm, G. B. and The US Multicenter Study Group (1995) Hyperlipidemia after liver transplantation: long-term results of the FK506-cyclosporine. A US multicenter trial. Transplant. Proc. 27: 1121–1123.

3. Simvastatin-induced increase in the transfer of cholesterol esters from high density to very low and low density lipoproteins in normolipidemic subjects;Ahnadi;Atherosclerosis,1993

4. Mevinolin;Alberts;Proc. Natl. Acad. Sci. USA,1980

5. Myoglobinuric acute renal failure in a cardiac transplant recipient taking lovastatin and cyclosporine;Alejandro;J. Am. Soc. Nephrol.,1994

Cited by 204 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. High hepatic and plasma exposures of atorvastatin in subjects harboring impaired cytochrome P450 3A4∗16 modeled after virtual administrations and possibly associated with statin intolerance found in the Japanese adverse drug event report database;Drug Metabolism and Pharmacokinetics;2023-04

2. Simvastatin therapy in different subtypes of hypercholesterolemia – a physiologically based modelling approach;2023-02-02

3. In Vivo Drug Metabolite Kinetics;Drug Metabolism Handbook;2022-11-18

4. Applications of Microbial Fermentation to Food Products, Chemicals and Pharmaceuticals;Advanced Fermentation and Cell Technology;2021-10-15

5. Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making;Pharmaceutics;2021-05-13